Genetic analysis of Mendelian mutations in a large UK population-based Parkinson's disease study. by Tan, MMX et al.
Genetic analysis of Mendelian mutations
in a large UK population-based
Parkinson’s disease study
Manuela M.X. Tan,1,2 Naveed Malek,3 Michael A. Lawton,4 Leon Hubbard,5 Alan
M. Pittman,1 Theresita Joseph,1 Jason Hehir,6 Diane M.A. Swallow,3 Katherine A. Grosset,3
Sarah L. Marrinan,7 Nin Bajaj,8 Roger A. Barker,2,9,10 David J. Burn,7 Catherine Bresner,5
Thomas Foltynie,1,2 John Hardy,11 Nicholas Wood,1,2 Yoav Ben-Shlomo,4
Donald G. Grosset,3 Nigel M. Williams5 and Huw R. Morris1,2 on behalf of the PRoBaND
clinical consortium
Our objective was to deﬁne the prevalence and clinical features of genetic Parkinson’s disease in a large UK population-based
cohort, the largest multicentre prospective clinico-genetic incident study in the world. We collected demographic data, Movement
Disorder Society Uniﬁed Parkinson’s Disease Rating Scale scores, and Montreal Cognitive Assessment scores. We analysed muta-
tions in PRKN (parkin), PINK1, LRRK2 and SNCA in relation to age at symptom onset, family history and clinical features. Of the
2262 participants recruited to the Tracking Parkinson’s study, 424 had young-onset Parkinson’s disease (age at onset450) and
1799 had late onset Parkinson’s disease. A range of methods were used to genotype 2005 patients: 302 young-onset patients were
fully genotyped with multiplex ligation-dependent probe ampliﬁcation and either Sanger and/or exome sequencing; and 1701 late-
onset patients were genotyped with the LRRK2 ‘Kompetitive’ allele-speciﬁc polymerase chain reaction assay and/or exome sequen-
cing (two patients had missing age at onset). We identiﬁed 29 (1.4%) patients carrying pathogenic mutations. Eighteen patients
carried the G2019S or R1441C mutations in LRRK2, and one patient carried a heterozygous duplication in SNCA. In PRKN, we
identiﬁed patients carrying deletions of exons 1, 4 and 5, and P113Xfs, R275W, G430D and R33X. In PINK1, two patients
carried deletions in exon 1 and 5, and the W90Xfs point mutation. Eighteen per cent of patients with age at onset 430 and 7.4%
of patients from large dominant families carried pathogenic Mendelian gene mutations. Of all young-onset patients, 10 (3.3%)
carried biallelic mutations in PRKN or PINK1. Across the whole cohort, 18 patients (0.9%) carried pathogenic LRRK2 mutations
and one (0.05%) carried an SNCA duplication. There is a signiﬁcant burden of LRRK2 G2019S in patients with both apparently
sporadic and familial disease. In young-onset patients, dominant and recessive mutations were equally common. There were no
differences in clinical features between LRRK2 carriers and non-carriers. However, we did ﬁnd that PRKN and PINK1 mutation
carriers have distinctive clinical features compared to young-onset non-carriers, with more postural symptoms at diagnosis and less
cognitive impairment, after adjusting for age and disease duration. This supports the idea that there is a distinct clinical proﬁle of
PRKN and PINK1-related Parkinson’s disease. We estimate that there are approaching 1000 patients with a known genetic
aetiology in the UK Parkinson’s disease population. A small but signiﬁcant number of patients carry causal variants in LRRK2,
SNCA, PRKN and PINK1 that could potentially be targeted by new therapies, such as LRRK2 inhibitors.
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Introduction
Parkinson’s disease is a progressive neurological condition
which affects 140/100 000 individuals within the UK
(Wickremaratchi et al., 2009). It is caused by genetic mu-
tations in LRRK2, SNCA, PRKN (also known as parkin or
PARK2), and PINK1 in up to 10% of patients (Lesage and
Brice, 2012; Puschmann, 2013; Lubbe and Morris, 2014).
These genetic factors also inﬂuence clinical features of the
disease, such as age at onset (Clark et al., 2007; Golub
et al., 2009; Lesage and Brice, 2012; Klebe et al., 2013;
Cilia et al., 2016), motor features, presenting symptoms,
disease progression (Davis et al., 2016) and cognition
(Alcalay et al., 2012; Mata et al., 2015; Crosiers et al.,
2016).
Many previous studies have focused on highly selected
cohorts recruited from specialist clinics. This is likely to
lead to bias both in estimates of frequency and clinical
characteristics associated with speciﬁc genetic mutations.
To overcome these issues, we designed the ‘Tracking
Parkinson’s study’, a large-scale population-based prospect-
ive cohort study of recently diagnosed and young-onset
Parkinson’s disease patients in the UK. It is the largest
single cohort study of genetic mutations in Parkinson’s dis-
ease and is relatively unbiased. Analysis of this cohort is
important to: (i) develop more accurate estimates of genetic
risk and the likelihood of a known genetic cause overall
and in speciﬁc patient subgroups; (ii) estimate the likeli-
hood of further high risk genes that have not yet been
identiﬁed; and (iii) understand the contribution of
Mendelian gene variation to the phenotype of Parkinson’s
disease.
Several studies have examined the frequency of gene mu-
tations in early-onset Parkinson’s disease patients (Alcalay
et al., 2010a; Kilarski et al., 2012). However, some muta-
tions, such as LRRK2, are also present at a signiﬁcant rate
in non-familial late-onset Parkinson’s disease patients (Clark
et al., 2006). Previous studies have also sometimes used
single techniques such as partial Sanger sequencing, which
are not able to detect copy number variation common in
PRKN and less common point mutations. In our analysis,
mutations were comprehensively identiﬁed using a range of
different genetic screening methods, including whole-exome
sequencing, multiplex ligation-dependent probe ampliﬁcation
(MLPA) and Sanger sequencing.
The aim of this study is to describe the frequency of
pathogenic Mendelian gene variants in the general
Parkinson’s disease population and in speciﬁc disease sub-
groups. In addition, we sought to understand the relation-
ship between Mendelian mutations and clinical phenotype
at presentation.
Materials and methods
Patients were recruited to the Tracking Parkinson’s study from sites
across the UK. Patients were required to have a clinical diagnosis of
Parkinson’s disease fulﬁlling Queen Square Brain Bank criteria
(Hughes et al., 2001). This project was funded by Parkinson’s
UK and supported by the National Institute for Health Research.
Patients with disease duration of53.5 years at time of diagnosis
were recruited as ‘recent onset’ participants. Patients with disease
duration of43.5 years at time of diagnosis and age at onset4 50
years were recruited as ‘established young-onset’ participants.
Patients were recruited regardless of ethnicity, including Jewish eth-
nicity. Full eligibility criteria, exclusion criteria and methods of re-
cruitment have been described previously (Malek et al., 2015).
Importantly, unlike most studies of this type, patients were re-
cruited irrespective of any prior information on genetic status.
Motor and non-motor features were assessed using standar-
dized and validated scales, including the Movement Disorder
Society Uniﬁed Parkinson’s Disease Rating Scale (MDS-
UPDRS), Hoehn and Yahr stage and Montreal Cognitive
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Assessment (MoCA). Full details are provided in the
Supplementary material.
Pathogenic mutations in the studied genes were deﬁned ac-
cording to MDSGene (http://www.mdsgene.org) (Lill et al.,
2016; Kasten et al., 2018), and the Parkinson Disease
Mutation Database (PDmutDB; http://www.molgen.vib-ua.be/
Parkinson’s diseaseMutDB/). Variants that did not meet patho-
genicity criteria according to MDSGene (variants classiﬁed as
‘benign’) were not reported.
Genetic analysis of Parkinson’s
disease gene mutations
At study entry, blood samples were collected from every
participant and DNA was extracted from an EDTA sample.
We screened for mutations in PRKN, PINK1 and GBA with
Sanger sequencing. As GBA is considered a risk gene for
Parkinson’s rather than a pathogenic single gene cause, we
reported the results of GBA sequencing separately (Malek
et al., 2018).
Whole exome sequencing was performed in a subset of
young-onset and familial patients (n = 489) (Supplementary
material). Exome sequencing data was screened for pathogenic
variants in SNCA, LRR2K2, PRKN, PINK1, PARK7/DJ1 and
VPS35.
Genotyping in young-onset and
late-onset patients
Genotyping was carried out on 2106 patients with Parkinson’s
disease for the LRRK2 G2019S mutation using the
‘Kompetitive’ allele-speciﬁc polymerase chain reaction (KASP)
assay (LGC Genomic Solutions).
We performed SNP array genotyping for 2116 samples.
Samples were genotyped using the Illumina HumanCore
Exome array supplemented with custom content, including
over 27 000 custom variants that have been previously impli-
cated in neurological, neurodegenerative and psychiatric con-
ditions (Malek et al., 2015). For imputation, genotypes were
aligned to the 1000 Genomes Phase 3 v5 mixed population
reference panel (Auton et al., 2015) (build hg19/ GRCh37)
and imputed using Minimac3 (Das et al., 2016) on the
Michigan Imputation Server (Supplementary material).
Genotyping in young-onset patients
Patients with age at onset 450 were screened for point muta-
tions in PRKN and PINK1 using Sanger sequencing
(Supplementary Fig. 2). We also performed MLPA to detect
and conﬁrm copy number variation in PRKN, PINK1,
PARK7/DJ1 and SNCA. MLPA was performed with the
MRC Holland SALSA MLPA P051 Parkinson kit (version
D1), according to the manufacturer’s instructions. Of 424 pa-
tients, 291 (68.7%) were successfully genotyped for PRKN
and PINK1 with both MLPA and Sanger sequencing. Eleven
patients were screened for copy number variants using MLPA
but were not Sanger sequenced. Exome sequencing was per-
formed in 269 patients.
For our ﬁnal phenotype-genotype analyses, we included
young-onset patients if both MLPA and either Sanger or
exome sequencing, had been completed. The combination of
these methods was selected in order to detect both copy
number variants and point mutations in PRKN and PINK1.
In total, 302 patients with age at onset 450 were included for
ﬁnal analysis.
Genotyping in late-onset patients
Exome sequencing was performed in 219 late-onset patients
with a positive family history of Parkinson’s disease and one
patient with missing age at onset and a positive family history.
In late-onset patients with two or more additional family
members affected by Parkinson’s disease, MLPA was per-
formed in 65 of 74 (87.8%) patients.
For the ﬁnal phenotype-genotype analyses, we included late-
onset patients if either LRRK2 KASP genotyping or exome
sequencing had been successfully completed. In total, 1701
late-onset patients were included for ﬁnal analysis, as well as
two patients with missing age at onset.
In total, 2005 patients with Parkinson’s disease were
included for ﬁnal analysis (302 young-onset, 1701 late-onset,
two missing age at onset).
Mutations of uncertain pathogenicity
From the exome sequencing data, we report on the frequency
of variants that have been previously reported in Parkinson’s
disease or parkinsonism but whose pathogenicity is uncertain
(Supplementary material and Supplementary Table 4).
This study was not designed to conﬁrm pathogenicity of
variants through segregation or comparison of allele frequen-
cies in cases and controls. However, we report allele frequen-
cies in our cohort from exome sequencing alongside allele
frequencies in controls obtained from gnomAD (http://
gnomad.broadinstitute.org/).
Haplotype and relatedness analysis
Unimputed genotype data were used for pairwise identity-by-
descent (IBD) analysis. Imputed genotype data were used for
haplotype analysis. Individual haplotypes were constructed
manually for mutation carriers. The markers used to construct
haplotypes are detailed in the Supplementary material.
Statistical analyses
Demographic characteristics were compared using t-tests,
Fisher’s exact tests for proportions, or two-sample proportion
tests. Linear regression was used for comparisons of demo-
graphic characteristics with covariate adjustment. To assess
the association between clinical outcomes and genetic status,
we used linear regressions of continuous scores against gene
status (mutation positive or mutation negative) adjusting for
age at assessment, disease duration at study entry, sex and
LEDD. Hoehn and Yahr stage, MoCA subdomain and dys-
tonia comparisons were conducted using ordered logistic re-
gression. Motor subtype was analysed using multinomial
logistic regression with the tremor dominant group as the com-
parator. All P-values were 2-tailed. We applied the Bonferroni
correction for multiple testing for the number of independent
tests in Tables 5 and 7. Statistical analysis was conducted
using STATA (version 14, StataCorp, Texas, USA) and R (ver-
sion 3.5.1).
Mendelian Parkinson’s disease in a large UK cohort BRAIN 2019: 0; 1–17 | 3
D
ow
nloaded from
 https://academ
ic.oup.com
/brain/advance-article-abstract/doi/10.1093/brain/aw
z191/5536358 by guest on 31 July 2019
Prevalence estimates
We estimated the absolute numbers of Parkinson’s disease pa-
tients with a Mendelian genetic cause in the UK using the
following approach in recent-onset patients only. Patients
with established young-onset disease were not included for
the prevalence estimate calculations. We used age-speciﬁc
prevalence rates from a previous UK meta-analysis
(Wickremaratchi et al., 2009) and applied the rates to the
Ofﬁce of National Statistics Great Britain mid-2016 popula-
tion estimates (Ofﬁce for National Statistics, 2017) to derive
an approximate number of all Parkinson’s disease patients.
The age distribution of the Parkinson’s disease population
(as a percentage) was used to standardize the rates of genetic
Parkinson’s disease within our cohort (per 100 000). From
this, we derived the new age-standardized rate of genetic
Parkinson’s disease. We applied this age-standardization
method because our over-sampling of young-onset cases had
resulted in a non-representative age-distribution of patients.
This new rate was then applied to the total Parkinson’s disease
population to estimate the absolute number of patients with a
Mendelian genetic cause in the UK population. It is important
to note that, as we have derived the rates from our incident
cases (excluded established young-onset cases), we have
assumed that the rates are representative of all prevalent
cases. This may not be true if these Mendelian forms of
Parkinson’s disease are associated with better or worse sur-
vival, in which case our estimates will be either an under- or
overestimate of the true numbers. Ninety-ﬁve per cent conﬁ-
dence intervals were calculated using the Poisson distribution.
Data availability
The anonymized data from this study are available to re-
searchers, to support other studies. Please apply via the
Tracking Parkinson’s project coordinator (tracking-
parkinsons@glasgow.ac.uk).
Results
Table 1 shows the baseline demographics for participants
that met Parkinson’s disease diagnostic criteria. Data are
presented separately for three groups below, according to
inclusion criteria for recruitment. Here we deﬁned young-
onset as patients with age at onset 450 (Malek et al.,
2015). Young-onset patients were separated into recent
and established patients, as only the recent onset patients
represent an incident, largely population-based cohort of
Parkinson’s disease. For this reason, only recent onset
Table 1 Baseline demographics for all Parkinson’s disease patients with known age at onset
Recent, late-onset
patients (AAO `50,
43.5 years from
diagnosis) n = 1799
Recent, young-onset
patients (AAO 450,
43.5 years from
diagnosis) n = 197
Established young-onset
patients (AAO 450,
`3.5 years from
diagnosis) n = 227
Total
n = 2223
Age at recruitment, years (SD) 69.3 (7.5) 48.8 (6.2) 54.5 (7.7) 66.0 (10.2)
Age at onset, years (SD) 66.4 (7.7) 43.7 (5.6) 41.1 (7.1) 61.8 (12.1)
Disease duration at diagnosis, years (SD) 1.3 (0.9) 1.4 (1.0) 11.4 (6.4) 2.4 (3.8)
Disease duration at entry, years (SD) 2.9 (2.1) 5.2 (6.6) 13.1 (7.4) 4.0 (4.6)
Family history, n (%)
No family history 1442 (80.2) 145 (73.6) 166 (73.1) 1753 (78.9)
One additional affected family member 267 (14.8) 41 (20.8) 47 (20.7) 355 (16.0)
Two additional affected family members 59 (3.3) 8 (4.1) 8 (3.5) 75 (3.4)
Three additional affected family members 11 (0.6) 2 (1.0) 4 (1.8) 17 (0.8)
Four or more additional affected family
members
4 (0.2) 0 (0.0) 1 (0.4) 5 (0.2)
Consistent with dominant inheritance 305 (17.0) 49 (24.9) 57 (25.1) 411 (18.5)
Consistent with recessive inheritance 36 (2.0) 2 (1.0) 3 (1.3) 41 (1.8)
Consanguinity (%)
Non-consanguineous 1741 (96.8) 191 (97.0) 220 (96.9) 2152 (96.8)
Consanguineous 16 (0.9) 2 (1.0) 2 (0.9) 20 (0.9)
Ethnicity (%)
White 1742 (96.8) 188 (95.4) 211 (93.0) 2141 (96.3)
Asian or Asian British 16 (0.9) 3 (1.5) 8 (3.5) 27 (1.2)
Black or Black British 10 (0.6) 3 (1.5) 2 (0.9) 15 (0.7)
Chinese 0 (0.0) 0 (0.0) 2 (0.9) 2 (0.1)
Mixed 4 (0.2) 0 (0.0) 0 (0.0) 4 (0.2)
Other 2 (0.1) 1 (0.5) 0 (0.0) 3 (0.1)
Sex (%)
Male 1181 (65.7) 124 (62.9) 149 (65.6) 1454 (65.4)
AAO = age at onset.
Consistent with dominant inheritance = family members from multiple generations affected.
Consistent with recessive inheritance = family members only from the same generation affected.
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patients were used to estimate the prevalence of genetic
forms of Parkinson’s disease in the UK.
(i) Recent late-onset Parkinson’s disease patients (age at onset
450, disease duration 43.5 years at time of diagnosis);
(ii) Recent young-onset Parkinson’s disease patients (age at onset
450, disease duration 43.5 years at time of diagnosis);
(iii) Established young-onset Parkinson’s disease patients (age at
onset 450, disease duration43.5 years at time of diagnosis).
Thirty-seven patients received a revised alternative diag-
nosis other than Parkinson’s disease or had conﬂicting
dopamine transporter (DaT) scan results and were excluded
from further analysis. On rare occasions, LRRK2 muta-
tions may be present in progressive supranuclear palsy or
atypical parkinsonian patients (Sanchez-Contreras et al.,
2017; Vilas et al., 2018); however, we did not identify
any pathogenic mutations in these patients.
Summary of genotyping
Supplementary Figs 1–5 show the number of patients that
were genotyped with each method. The shaded boxes high-
light the samples that were included for analysis. There
were approximately 100 patients for which DNA was not
available for genotyping (this varied between different
methods). These patients were excluded from phenotype-
genotype analyses.
For young-onset patients, we included samples for ﬁnal
analysis if MLPA had been completed, and either Sanger
sequencing or exome sequencing or both had been success-
fully completed. In total, 302 patients with age at onset
450 were included for ﬁnal analysis of PRKN and PINK1.
For late-onset patients, we included patients for ﬁnal ana-
lysis if the samples had been genotyped with the LRRK2
KASP assay for G2019S, and/or exome sequencing. In
total, 1701 late-onset patients were included for ﬁnal ana-
lysis, as well as two patients with missing age at onset.
In total, 2005 patients with Parkinson’s disease were
included for ﬁnal analysis (302 young-onset, 1701 late-
onset, two missing age at onset).
Summary of mutations identified
We identiﬁed 14 different pathogenic mutations in LRRK2,
SNCA, PRKN and PINK1 in 29 of 2005 patients [1.4%,
95% conﬁdence interval (CI) 0.9–2.0%] (Tables 2 and 3).
This estimate is conservative as not all samples were com-
prehensively tested, therefore the true mutation rate may be
higher.
Eighteen patients carried a mutation in LRRK2, one pa-
tient carried an SNCA mutation, eight patients carried bial-
lelic PRKN mutations and two patients carried biallelic
PINK1 mutations. No patients were found carrying patho-
genic mutations in VPS35 or PARK7 (DJ1). No patient
carried pathogenic mutations in more than one gene.
Three patients carried the LRRK2 G2019S mutation and
additionally one or more mutations in GBA (p.E326K and
p.P122H). The mean age at onset for patients carrying mu-
tations in both LRRK2 and GBA was 43.2 years [standard
deviation (SD) = 5.1], compared to an age at onset of 56.5
years (SD = 12.9) for LRRK2 mutation carriers without
GBA mutations. Pathogenic carriers are shown in
Supplementary Table 1 and the list of unique mutations
are shown in Supplementary Table 2.
We identiﬁed nine patients carrying single heterozygous
pathogenic mutations in PRKN and PINK1 (Supplementary
Table 3). Previous analysis of this cohort showed no differ-
ences between carriers of single heterozygous PRKN muta-
tions (including mutations of uncertain pathogenicity) and
non-carriers other than in olfaction (Malek et al., 2016),
therefore patients with single heterozygous mutations in re-
cessive genes were analysed as non-carriers.
One patient carried three pathogenic mutations in PRKN
(Supplementary Table 1).
Table 2 Overall frequency of dominant gene mutation carriers in successfully genotyped patients
Young onset n = 408 Late onset n = 1701 All n = 2003
LRRK2 9 (2.2%; 0.8–3.6%) 9 (0.5%; 0.2–0.9%) 18 (0.9%; 0.5–1.3%)
SNCA 0 (0%; 0.0–0.9%) 1 (0.06%; 0.01–0.3%) 1 (0.05%; 0.04–0.1%)
All autosomal dominant (LRRK2 and SNCA) 9 (2.2%; 0.8–3.6%) 10 (0.6%; 0.2–1.0%) 19 (0.9%; 0.5–1.4%)
Percentages and 95% CIs are shown in parentheses.
Table 3 Overall frequency of biallelic recessive gene
mutation carriers for known pathogenic variants in
successfully genotyped young-onset patients (age at
onset 450)
Young onset
n = 302
PRKN
Homozygous 0 (0%; 0.0–0.1.3%)
Compound heterozygous 8 (2.6%; 0.8–4.5%)
PINK1
Homozygous 1 (0.3%; 0.06–1.9%)
Compound heterozygous 1 (0.3%; 0.06–1.9%)
All autosomal recessive
(PRKN and PINK1 biallelic mutations)
10 (3.3%; 1.3–5.3%)
Percentages and 95% CIs are shown in parentheses.
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Mutations were common in patients with very young
onset and patients with multiple family members also af-
fected by Parkinson’s disease. Of Parkinson’s disease pa-
tients with onset 430, 18.8% (3/16; 95% CI 6.6–43.0%)
carried pathogenic mutations. In young-onset patients,
18.2% (4/22; 95% CI 7.3–38.5%) of patients with two
or more additional affected family members carried patho-
genic mutations. In late-onset patients, 4.2% (3/72; 95%
CI 1.4–11.5%) of patients with two or more additional
affected family members carried pathogenic mutations.
Notably, the LRRK2 G2019S mutation was more
common in young-onset patients (2.2%, 9/408; 95% CI
0.7–3.6%) than in later-onset patients (0.4%, 7/1701;
95% CI 0.1–0.7%), P = 0.001 [Fisher’s exact test, odds
ratio (OR) = 5.5, 95% CI 1.8–17.3]. In addition, young-
onset patients were equally likely to have recessive (2.5%,
10/408) and dominant pathogenic mutations (2.2%, 9/
408).
Pathogenic mutations were only identiﬁed in patients re-
porting ‘White’ ethnicity (n = 2005 genotyped).
IBD analysis was conducted based on 25 781 single nu-
cleotide polymorphisms (SNPs) in linkage equilibrium. This
showed that none of the mutation carriers were related to
each other (pi-hat 50.1 for all, indicating no closer rela-
tions than third-degree relatives).
Constructed haplotypes and the results of haplotype ana-
lysis are shown in Supplementary Figs 6–9).
LRRK2
We identiﬁed 18 patients carrying heterozygous LRRK2
mutations, either G2019S (n = 16) or R1441C (n = 2).
55.6% (10/18) carriers reported a positive family history
of Parkinson’s disease.
Both LRRK2 R1441C carriers reported a family history
of Parkinson’s disease. As we only screened for the
R1441C mutation through exome sequencing in familial
and/or young-onset patients, our results for R1441C
cannot be used to compare familial versus non-familial
patients.
We only included LRRK2 G2019S mutation carriers for
our analysis of family history. G2019S mutations were
more common among patients with a positive family his-
tory (1.9%, 95% CI 0.5–3.1%) than patients without a
family history of Parkinson’s disease (0.5%, 95% CI 0.1–
0.8%), P = 0.009 (Fisher’s exact test, OR = 3.9, 95% CI
1.3–11.8). However, within the G2019S carriers, 50%
had a positive family history and 50% did not have a
family history of Parkinson’s (50%, 95% CI 25.5–74.5%).
LRRK2 mutation carriers (G2019S and R1441C carriers
together) had an earlier mean age at onset (54.3 years,
95% CI 47.9–60.7) compared to non-carriers (61.7 years,
95% CI 61.2–62.2; P = 0.01). Age at onset for LRRK2
carriers ranged from 35.2 to 78.7 years. LRRK2 mutations
were more frequent in young-onset (2.2%, 95% CI 1.0–
4.2%) compared to late-onset patients (0.5%, 95% CI 0.2–
1.0%), P = 0.003 (Fisher’s exact test, OR = 4.2, 95%
CI = 1.5–12.1).
Clinical features of LRRK2 carriers compared to non-
carriers are presented in Table 5 (excluding patients with
recessive gene mutations). We did not include the SNCA
carrier in this analysis given that previous literature sug-
gests that LRRK2 and SNCA mutation carriers have dif-
ferent clinical features (Trinh et al., 2018). We did not ﬁnd
any differences in clinical features between LRRK2 carriers
and non-carriers.
SNCA
SNCA copy number variants were screened with MLPA in
65 patients with familial Parkinson’s disease with two or
more family members affected. One patient (1.5%) carrying
Table 4 Rate of known dominant pathogenic mutations based on clinical presentation
LRRK2 n = 18 SNCA n = 1 Rate of all pathogenic
dominant mutations
Age at onset (%)
420 years, n = 4 0/4 (0) 0/4 (0) 0/4 (0)
430 years, n = 18 0/18 (0) 0/18 (0) 0/18 (0)
440 years, n = 118 2/118 (1.7) 0/118 (0) 2/118 (1.7)
450 years, n = 408 9/408 (2.2) 0/408 (0) 9/408 (2.2)
460 years, n = 784 10/784 (1.3) 1/784 (0.1) 11/784 (1.4)
470 years, n = 1552 17/1552 (1.1) 1/1552 (0.06) 18/1552 (1.2)
480 years, n = 2050 18/2050 (0.9) 1/2050 (0.05) 19/2050 (0.9)
All, n = 2109 18/2109 (0.9) 1/2109 (0.05) 19/2109 (0.9)
Mean age of onset in years (SD) 54.3 (12.9) - 54.1 (12.6)
Family history (%)
No other family members affected 8/1658 (0.5) 0/1658 (0) 8/1658 (0.5)
One other family member affected 7/344 (2.0) 0/344 (0) 7/344 (2.0)
Two other family members affected 1/72 (1.4) 1/72 (1.4) 2/72 (2.8)
Three other family members affected 2/17 (11.8) 0/17 (0) 2/17 (11.8)
Four or more family members affected 0/5 (0) 0/5 (0) 0/5 (0)
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Table 5 Comparison of motor features, fluctuations and non-motor features by LRRK2 mutation status (LRRK2
carriers versus non-carriers)
Variable Mutation negative
n = 2082
LRRK2
positive
n = 18
Beta (95% CI) LRRK2
carriers versus
non-carriers
P-valuea
Age at entry, years 66.0 (10.1) 60.1 (10.4) 5.2 (9.9, 0.5) 0.030b
Age at onset, years 61.8 (11.9) 54.3 (12.9) 5.2 (9.9, 0.5) 0.030b
Disease duration, years 4.0 (4.4) 5.2 (4.5) 0.7 (1.3, 2.8) 0.482c
Delay to diagnosis (time from symptom onset to diagnosis), years 1.8 (2.9) 1.5 (1.3) 0.4 (1.8, 1.0) 0.580c
Motor features
MDS-UPDRS III total score 23.4 (12.7) 28.6 (15.2) 6.7 (0.1, 13.3) 0.047
Severity score MDS-UPDRS-III/years from symptom onset 10.4 (11.8) 9.4 (7.3) 0.6 (5.7, 6.8) 0.862d
Upper limb score, max 56 10.7 (6.3) 12.1 (6.3) 2.1 (0.9, 5.1) 0.163
Lower limb score, max 32 5.1 (3.9) 6.8 (5.5) 1.7 (0.2, 3.6) 0.085
Gait and freezing, max 8 1.1 (1.1) 1.6 (1.7) 0.4 (0.1, 0.9) 0.097
Hoehn and Yahr stage 0.3 (0.7, 1.2) 0.595
0–1.5 (%) 950 (46.0) 7 (38.9)
2 or 2.5 (%) 957 (46.3) 10 (55.6)
3 + (%) 160 (7.7) 1 (5.6)
Symptoms present at diagnosis (%)
Tremor 1499/2017 (74.3) 13/18 (72.2) 0.3 (0.8, 1.6) 0.586
Rigidity 1410/1925 (73.2) 13/18 (72.2) 0.08 (1.2, 1.2) 0.891
Bradykinesia 1554/1966 (79.0) 12/18 (66.7) 0.8 (1.8, 0.3) 0.121
Postural problems 363/1898 (19.1) 4/18 (22.2) 0.009 (1.5, 1.2) 0.989
Other 456/1827 (25.0) 4/16 (25 ) 0.2 (1.1, 1.3) 0.731
Motor subtype
Tremor dominant 835/1892 (44.1) 7/17 (41.2)
Non-tremor dominant (PIGD) 813/1892 (43.0) 10/17 (58.8) 2.8 (0.5, 1.8) 0.246
Mixed 244/1892 (12.9) 0/17 (0) 8.7 (NA)e NAe
Motor complications
MDS-UPDRS-IV total score 1.3 (2.8) 2.8 (3.3) 0.1 (0.9, 1.2) 0.794
Dyskinesias (MDS-UPDRS IV part 1 and 2 sum, max 8) 0.3 (1.0) 0.4 (0.9) 0.2 (0.5, 0.1) 0.259
Fluctuations (MDS-UPDRS IV part 3–5 sum, max 12) 0.9 (1.9) 2.1 (2.6) 0.3 (0.4, 1.1) 0.408
Dystonia, max 4 0.2 (0.6) 0.3 (0.6) 0.01 (0.2, 0.3) 0.915
Non-motor features
Cognition: total MoCA score 25.2 (3.5) 25.4 (3.2) 0.2 (1.9, 1.4) 0.761
Visuospatial, max 5 4.3 (1.1) 4.2 (1.2) 0.2 (0.7, 0.3) 0.359
Naming, max 3 2.9 (0.3) 2.9 (0.3) 0.05 (0.2, 0.1) 0.535
Attention, max 6 5.2 (1.0) 5.3 (0.8) 0.1 (0.4, 0.6) 0.690
Language, max 3 2.4 (0.8) 2.4 (0.7) 0.03 (0.4, 0.3) 0.865
Abstraction, max 2 1.6 (0.6) 1.7 (0.7) 0.003 (0.3, 0.3) 0.983
Recall, max 5 2.7 (1.6) 2.9 (1.8) 0.05 (0.7, 0.8) 0.898
Orientation, max 6 5.8 (0.5) 5.8 (0.5) 0.03 (0.2, 0.2) 0.756
LADS Anxiety score, max 18) 4.5 (3.8) 5.8 (3.8) 0.9 (0.8, 2.6) 0.287
LADS Depression score, max 18 4.5 (3.3) 5.1 (3.3) 0.3 (1.2, 1.8) 0.706
Sleep disturbance, ESS score 7.1 (4.8) 9.7 (6.8) 1.6 (0.7, 3.8) 0.173
RBDSQ scale score 4.8 (3.2) 6.4 (3.5) 1.0 (0.5, 2.5) 0.191
Autonomic function: SCOPA total score 9.3 (5.8) 10.8 (6.4) 2.6 (1.1, 6.3) 0.170
Patients carrying biallelic recessive mutations and one patient carrying a SNCA mutation were excluded from analyses. Scores in the first two columns are means (SD), except for
Hoehn and Yahr stage, symptoms present at diagnosis and motor subtype which are shown as n or proportions (%). Increasing scores and increasing beta values for motor and non-
motor variables are associated with worse symptoms, with the exception of the MoCA test scores. Increasing scores and increasing beta values for the MoCA test are associated
with better cognition.
ESS = Epworth Sleep Scale; LADS = Leeds Anxiety and Depression Scale; MDS-UPDRS = Movement Disorder Society Unified Parkinson’s Disease Rating Scale; ; MoCA = Montreal
Cognitive Assessment; NA = not assessed; PIGD = postural instability gait difficulty; RBDSQ = Rapid Eye Movement Sleep Behaviour Disorder Screening Questionnaire;
SCOPA = Scales for Outcomes in Parkinson’s disease.
aP-value of clinical features of LRRK2 carriers together compared to non-carriers, excluding patients with recessive gene mutations and one patient with SNCA mutation. Adjusting for
age at entry, gender, disease duration at entry/assessment and LEDD total, unless otherwise specified.
bAdjusting for gender and disease duration at entry.
cAdjusting for gender and age at entry.
dAdjusting for age, gender and LEDD total.
eInsufficient count to fit model.
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a heterozygous whole gene duplication was identiﬁed, who
reported two additional family members affected by
Parkinson’s disease. We were unable to compare the clin-
ical features of SNCA carriers to non-carriers given that
only one SNCA carrier was identiﬁed.
Young-onset patients
We identiﬁed 19/302 (6.3%) young-onset patients carrying
pathogenic mutations in both dominant and recessive
genes. Here we deﬁned young-onset as patients with age
of onset 450. The proportions of mutation carriers by age
at onset and family history are presented in Table 6.
Recessive gene mutation carriers had an earlier mean age
at onset (32.7 years) compared to non-carriers (41.1 years),
P50.001, excluding dominant mutation carriers.
When considering all young-onset mutation carriers
(PRKN, PINK1, LRRK2 and SNCA), the mean age at
onset was also younger than non-carriers (37.5 versus
41.1 years; P = 0.02). Mutations were more frequent in pa-
tients with a positive family history (11.0%) than in pa-
tients with no family history of Parkinson’s disease (4.2%),
P = 0.04 (Fisher’s exact test, OR = 2.8, 95% CI 1.0–8.1).
PRKN
Of all young-onset patients that were successfully geno-
typed for PRKN, biallelic pathogenic PRKN mutations
were present in 2.6% (8/302, 95% CI 0.8–4.4%). No
PRKN carriers had homozygous mutations; all mutations
were present in compound heterozygous state.
PRKN mutations were present in 20% (3/15, 95% CI
7.0–45.2%) of young-onset patients with two additional
family members affected by Parkinson’s disease. However,
there was no signiﬁcant difference in the frequency of mu-
tations in early young-patients with a positive family his-
tory (4.2%, 95% CI 0.2–8.4%) and without a family
history of Parkinson’s disease (1.9%, 95% 0.05–3.7%),
P40.2 (Fisher’s exact test, OR = 2.3, 95% CI 0.4–12.9).
Young-onset patients from large Parkinson’s disease
families (two or more additional family members affected)
were more likely to carry a PRKN mutation (13.6%) than
young-onset patients with one or no additional family
members affected (1.6%), P = 0.01 (Fisher’s exact test,
OR = 8.5, 95% CI 1.2–47.9).
The clinical features of PRKN and PINK1 mutation car-
riers compared to young-onset non-carriers are presented in
Table 7. PRKN carriers had younger age at onset than
young-onset patients with LRRK2 mutations (42.9 years,
95% CI 39.3–46.6), P = 0.009. There was no difference in
age at onset of PRKN and PINK1 carriers, P4 0.2.
PINK1
Biallelic PINK1 mutations were present in 0.7% (2/302,
95% CI 0.2–2.4%) of all screened young-onset patients.
Mutations were present in 1.1% (1/89) of young-onset pa-
tients with a positive family history and 0.5% (1/213) of
patients with no family history of Parkinson’s disease.
Mutations were not more frequent in patients with a posi-
tive family history, P = 0.50 (Fisher’s exact test, OR = 2.4,
95% CI 0.03–189.7).
PRKN and PINK1 mutation carriers had earlier age at
onset than other young-onset non-carriers, adjusting for
gender and disease duration (Table 7). They also had
longer disease duration than non-carriers, adjusting for
age at entry and gender (Table 7).
PRKN and PINK1 mutation carriers also reported more
postural problems at diagnosis than non-carriers and
tended to report a higher rate of dyskinesias, after adjusting
for age at entry, gender, disease duration and LEDD total,
although this did not survive correction for multiple testing.
They also tended to have more gait and freezing problems
at assessment, after adjusting for age, gender, disease dur-
ation and LEDD total (P = 0.021), although this was not
signiﬁcant after correction for multiple testing.
Table 6 Cumulative rate of pathogenic mutations based on clinical presentation in successfully genotyped young-
onset Parkinson’s disease patients (age at onset4 50), n = 302
PINK1 (biallelic) n = 2 PRKN (biallelic) n = 8 All recessive gene
mutations n = 10
Age at onset (%)
420 years, n = 4 0/4 (0) 2/4 (50) 2/4 (50)
430 years, n = 18 0/16 (0) 3/16 (18.8) 3/16 (18.8)
440 years, n = 118 1/110 (0.9) 6/110 (5.5) 7/110 (6.4)
450 years, n = 408 2/302 (0.7) 8/302 (2.6) 10/302 (3.3)
Mean age of onset in years (SD) 42.3 (5.5) 30.3 (11.5) -
Family history (%)
No other family members affected 1/213 (0.5) 4/213 (1.9) 5/213 (2.3)
One other family member affected 1/67 (1.5) 1/67 (1.5) 2/67 (3.0)
Two other family members affected 0/15 (0) 3/15 (20) 3/15 (20)
Three other family members affected 0/6 (0) 0/6 (0) 0/6 (0)
Four or more other family members affected 0/1 (0) 0/1 (0) 0/1 (0)
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Table 7 Comparison of motor features, fluctuations and non-motor features of young-onset patients by recessive
gene status (PRKN and PINK1 carriers versus non-carriers), excluding patients carrying dominant gene mutations
Variable Mutation-negative Mutation-positive (biallelic) Beta (95% CI) P-valuea
n = 292 Total, n = 10 PRKN, n = 8 PINK1, n = 2 Carriers versus non-carriers
Age at entry, years 51.9 (8.1) 50.9 (11.1) 51.8 (12.2) 47.5 (5.9) 7.0 (10.9, 3.1) 0.001b
Age at onset, years 41.1 (6.2) 32.7 (11.5) 30.3 (11.5) 42.3 (5.5) 7.0 (10.9, 3.1) 0.001b
Disease duration, years 10.4 (7.6) 18.2 (14.4) 21.9 (14.4) 5.2 (0.4) 8.9 (5.0, 12.7) _0.001c
Delay to diagnosis, years 2.4 (4.2) 4.5 (4.1) 5.2 (4.4) 2.2 (0.1) 2.2 (0.6, 5.1) 0.123c
Motor features
MDS-UPDRS-III total score 26.1 (14.9) 29.0 (24.0) 33.0 (23.6) 5.0 (n = 1) 3.3 (14.4, 7.8) 0.564
Severity score MDS-UPDRS-III/years
from symptom onset
4.1 (6.8) 2.4 (2.9) 2.7 (3.1) 0.9 (n = 1) 2.5 (7.7, 2.8) 0.356d
Upper limb score, max 56 11.6 (6.7) 13.9 (8.8) 15.3 (8.7) 8.5 (9.2) 1.1 (5.5, 3.3) 0.621
Lower limb score, max 32 6.2 (4.4) 7.7 (5.6) 8.5 (6.0) 4.5 (3.5) 0.1 (3.1, 3.0) 0.973
Gait and freezing, max 8 1.6 (1.5) 3.2 (1.9) 3.6 (1.7) 1.5 (2.2) 1.1 (0.03, 2.1) 0.043
Hoehn and Yahr stage 1.8 (0.1, 3.6) 0.049
0–1.5 (%) 107 (36.7) 1 (11.1) 1 (12.5) 0 (0) - -
2 or 2.5 (%) 140 (48.1) 4 (44.4) 3 (37.5) 1 (100) - -
3 + (%) 44 (15.1) 4 (44.4) 4 (50) 0 (0) - -
Symptoms present at diagnosis (%)
Tremor 188/263 (71.5) 7/10 (70.0) 6/8 (75.0) 1/2 (50.0) 0.9 (2.4 0.8) 0.275
Rigidity 204/255 (80) 8/9 (88.9) 6/7 (85.7) 2/2 (100) 0.7 (1.2, 3.7) 0.561
Bradykinesia 209/257 (81.3) 9/10 (90.0) 7/8 (87.5) 2/2 (100) 15.1 (55.4, NA) 0.986
Postural problems 39/252 (15.5) 6/9 (66.7) 6/7 (85.7) 0/2 (0) 2.3 (0.7, 4.0) 0.005
Other 54/229 (23.6) 3/9 (33.3) 3/7 (42.9) 0/2 (0) 0.4 (1.6, 2.0) 0.684
Motor subtype (%)
Tremor dominant 79/257 (30.7) 2/8 (25.0) 1/6 (16.7) 1/2 (50) - -
Non-tremor dominant (PIGD) 150/257 (58.4) 6/8 (75.0) 5/6 (83.3) 1/2 (50) 0.4 (1.4, 2.3) 0.646
Mixed/indeterminate 28/257 (10.9) 0/8 (0) 0/6 (0) 0/2 (0) -9.5 (NA, NA) 40.1
Motor complications
MDS-UPDRS-IV total score 5.0 (4.9) 6.2 (5.7) 6.1 (6.3) 6.5 (3.5) 2.3 (0.5, 4.5) 0.105
Dyskinesias, presence and severity; max 8 1.3 (1.9) 2.3 (2.5) 2.1 (2.8) 3.0 (1.4) 1.2 (0.03, 2.3) 0.04
Fluctuations, max 12 3.0 (2.9) 3.3 (4.0) 3.4 (4.3) 3.0 (4.2) 0.9 (0.8, 2.6) 0.309
Dystonia, max 4 0.7 (1.1) 0.6 (1.3) 0.6 (1.4) 0.5 (0.7) 0.1 (0.7, 0.8) 0.891
Non-motor features
Cognition: total MoCA score, max 30 25.6 (3.6) 27.6 (2.2) 27.4 (2.3) 29.0 (n = 1) 3.0 (0.8, 5.2) 0.007
Visuospatial, max 5 4.4 (1.1) 4.3 (0.5) 4.4 (0.5) 4.0 (n = 1) 0.07 (0.6, 0.8) 0.847
Naming, max 3 2.9 (0.3) 2.9 (0.3) 2.9 (0.4) 3.0 (0.0) 0.08 (1.2, 0.3) 0.441
Attention, max 6 5.1 (1.0) 5.6 (0.5) 5.5 (0.5) 6.0 (0.0) 0.9 (0.3, 1.6) 0.004
Language, max 3 2.5 (0.7) 2.3 (0.8) 2.4 (0.7) 2.0 (1.4) 0.07 (0.5, 0.4) 0.767
Abstraction, max 2 1.7 (0.6) 1.6 (0.7) 1.6 (0.7) 1.5 (0.7) 0.09 (0.4, 0.5) 0.704
Recall, max 5 3.1 (1.6) 4.2 (1.3) 4.3 (1.4) 4.0 (1.4) 0.9 (0.2, 2.0) 0.116
Orientation, max 6 5.7 (0.7) 6.0 (0.0) 6.0 (0.0) 6.0 (0.0) 0.3 (0.08, 0.6) 0.131
LADS Anxiety score, max 18 6.6 (4.2) 6.1 (2.6) 6.3 (2.8) 5.5 (2.1) 0.4 (3.3, 2.4) 0.763
LADS Depression score, max 18 5.8 (3.5) 5.8 (2.3) 6.4 (1.8) 3.5 (3.5) 0.2 (2.7, 2.4) 0.901
Sleep disturbance, ESS score 9.0 (5.7) 8.5 (7.6) 9.5 (8.3) 4.5 (2.1) 0.1 (4.2, 4.0) 0.961
RBDSQ scale score 5.8 (3.4) 4.3 (2.5) 4.4 (2.8) 4.0 (0.0) 1.2 (3.6, 1.1) 0.307
Autonomic function: SCOPA total score 10.8 (6.9) 12.3 (7.4) 9.5 (4.8) 20.5 (9.2) 0.1 (5.0, 5.3) 0.959
Scores in the first four columns are mean (SD), except for Hoehn and Yahr stage, symptoms present at diagnosis and motor subtype which are shown as n or proportions (%).
Increasing values and increasing betas for motor and non-motor variables are associated with worse symptoms, with the exception of the MoCA test scores. Increasing values and
increasing betas for the MoCA test are associated with better cognition. Cells with only a single case are indicated with (n = 1).
aP-value of clinical features of PRKN and PINK1 carriers together compared to non-carriers, excluding patients with dominant gene mutations. Adjusting for age at entry, gender,
disease duration at entry/assessment and LEDD total, unless otherwise specified.
bAdjusting for gender and disease duration at entry.
cAdjusting for gender and age at entry.
dAdjusting for age, gender and LEDD total.
MDS-UPDRS = Movement Disorder Society Unified Parkinson’s Disease Rating Scale; PIGD = postural instability gait difficulty; MoCA = Montreal Cognitive Assessment;
LADS = Leeds Anxiety and Depression Scale; ESS = Epworth Sleep Scale; RBDSQ = Rapid Eye Movement Sleep Behaviour Disorder Screening Questionnaire; SCOPA = Scales for
Outcomes in Parkinson’s disease.
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Finally, PRKN and PINK1 carriers had better cognition
than non-carriers as assessed by the MoCA, even after ad-
justing for age, gender, disease duration and LEDD
(P = 0.007). This appears to be driven by better perform-
ance in the attention subdomain (P = 0.004) though one
must be cautious in interpreting the subdomains as they
may be overly simplistic.
Genes of unconfirmed pathogenicity
for Parkinson’s disease
Patients carrying variants of unconﬁrmed pathogenicity and
risk variants for Parkinson’s disease identiﬁed from exome
sequencing are reported in Supplementary Table 4, includ-
ing variants in GIGYF2, CHDCHD2. These variants were
detected in cases, as previously described, but also almost
all occur in the control population and were not included
as pathogenic variants in our analysis.
We found comparable mutation/variant frequencies in
our cohort compared to controls, with the exception of
well-validated risk variants, such as MAPT (Martin et al.,
2001; Kwok et al., 2004). We did not ﬁnd any patients
carrying previously reported mutations in EIF4G1,
DNAJC6, FBXO7 and PLA2G6. Further case-control stu-
dies are needed to determine the role of variants in
SNCAIP, UCHL1 and other genes where we found small
differences in allele frequencies from control frequencies,
however these variants are unlikely to be pathogenic
Mendelian mutations.
Prevalence
In the recent onset cohort (both young-onset and late-
onset), the frequency of pathogenic mutations was 1.0%
(17/1787). This is a large-scale cohort unselected for age
at onset, family history and genetic status. From this, we
can estimate the frequency of pathogenic mutations in the
general UK Parkinson’s disease population. The crude
prevalence rate of genetic forms of Parkinson’s disease is
951 per 100 000 (95% CI 892–1013, using Poisson distri-
bution). Age speciﬁc rates are presented in Table 8. The
age-standardized rate of genetic forms of Parkinson’s dis-
ease was 708 per 100 000 (95% CI 657–762 per 100 000),
standardized to the mid-2016 Great Britain population.
This provides an estimate of 725 genetic Parkinson’s dis-
ease patients in a total of 102 403 patients in the UK cur-
rently living, using estimates from a meta-analysis
(Wickremaratchi et al., 2009) and the Ofﬁce of National
Statistics Great Britain population estimates for mid-2016
(Ofﬁce for National Statistics, 2017) assuming these genes
do not impact on survival (see ‘Materials and methods’
section). A recent report from Parkinson’s UK using pri-
mary care diagnosis estimated a larger number of
Parkinson’s disease patients in the UK (145 519) in 2018
(Parkinson’s UK, 2017). If this ﬁgure is more accurate, then
the number of genetic Parkinson’s disease cases would be
larger (estimated at 1030).
Discussion
This study represents the largest study examining the fre-
quency of known Parkinson’s disease gene mutations. We
report an overall frequency of mutations of 1.4% (29/
2005), across both young-onset and late-onset patients. In
combination with GBA gene analysis in the same cohort
(Malek et al., 2018), our results suggest that up to 10% of
Parkinson’s disease patients carry a genetic variant that
could potentially be targeted by new drug therapies. For
instance, G2019S and other mutations in the LRRK2
gene have been shown to increase kinase activity, and
LRRK2 kinase inhibitors that counteract this activity are
currently being tested in phase 1 clinical trials as a potential
therapeutic target for Parkinson’s disease (reviewed in
Table 8 Age specific and crude prevalence rate of genetic forms of Parkinson’s disease, using data from recent-onset
patients only
Age Parkinson’s disease
genetic patients in cohort
Total number of Parkinson’s disease
patients in cohort (screened)
Age specific rates per 100 000
Parkinson’s disease patients
0–29 0 0 0
30–39 1 11 9091
40–49 4 58 6897
50–59 4 219 1826
60–69 5 728 687
70–79 2 633 316
580 1 138 725
Total 17 1787 -
Crude prevalence per 100 000
Parkinson’s disease patients
951 (525–1442) - -
Age-adjusted prevalence per 100 000
Parkinson’s disease patientsa
708 (612–713) - -
aAge distribution derived from age-specific Parkinson’s disease rates (Wickremaratchi et al., 2009) applied to the UK mid-2016 population estimates (Office for National Statistics,
2017).
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Atashrazm and Dzamko, 2016; Taymans and Greggio,
2016; Alessi and Sammler, 2018).
The strengths of this study lie in the relatively unbiased,
population-based patient ascertainment. This increases the
generalizability of our ﬁndings, speciﬁcally the prevalence
estimates of Parkinson’s disease patients carrying patho-
genic mutations based on the incident recent-onset cohort.
A further strength of this study is inclusion of both early
and late-onset patients, where previous genetic studies have
focused on young-onset patients.
First, this has enabled us to more accurately estimate the
prevalence of mutations in the general Parkinson’s disease
UK population, assuming there are no survival effects,
rather than just in the subset of young-onset patients. We
show clearly that LRRK2 mutations are present at a sig-
niﬁcant rate in patients with onset under 50 years (2.2%),
and that SNCA mutations are present in 1.5% of patients
with a strong family history of Parkinson’s disease (two or
more additional family members affected).
Second, our ﬁndings suggest that there may be other
high-risk genes that have not yet been identiﬁed. In particu-
lar, further efforts in gene discovery can focus on the sub-
stantial proportion of patients with very early onset or who
have a large family history in which no known pathogenic
mutations have been identiﬁed.
Third, our ﬁndings have implications for genetic testing.
Although further work is needed to conﬁrm some results,
our data suggest that LRRK2 mutations are common in
young-onset Parkinson’s disease (2.2%) and should be
more regularly tested with appropriate genetic counselling.
Additionally, our results highlight the importance of sys-
tematically screening for copy number variants in PRKN,
PINK1 and SNCA, as these are not infrequent and may be
missed with sequencing methods such as exome sequencing.
Finally, we show there are systematic clinical differences
between recessive gene mutation carriers compared to
young-onset non-carriers. PRKN and PINK1 carriers
have more postural problems at diagnosis and better cog-
nition than other young-onset patients, even after adjusting
for age, disease duration, gender and LEDD.
LRRK2 and SNCA
Mutations in LRRK2 (PARK8, dardarin) were ﬁrst identi-
ﬁed in autosomal dominant, mostly late-onset families with
Parkinson’s disease (Funayama et al., 2002; Paisa´n-Ruı´z
et al., 2004; Zimprich et al., 2004). The reported frequency
of LRRK2 mutations varies widely; mutations are more
common in familial Parkinson’s disease (5–6%) (Di
Fonzo et al., 2005; Nichols et al., 2005) than in sporadic
disease (1%) (Gilks et al., 2005; Hernandez et al., 2005).
However, the frequency of mutations also differs according
to population, and the G2019S mutation may be more
common in Southern Europe than in Northern Europe
(Bonifati, 2007). The rate of mutations is particularly
high in Ashkenazi Jewish (up to 28%) and North African
patients (up to 41%) (Lesage et al., 2005, 2006; Ozelius
et al., 2006; Williams-Gray et al., 2006; Healy et al., 2008;
Puschmann, 2013). We found that LRRK2 mutations were
present at a rate of 0.9% overall, most commonly the
G2019S mutation (0.8%). Our ﬁndings are comparable
with a previous community-based cohort in the UK
(Williams-Gray et al., 2006) and other Caucasian North
American and UK cohorts with estimates between 0.4
and 1.7% (Deng et al., 2005; Farrer et al., 2005;
Hernandez et al., 2005; Zabetian et al., 2005). Our results
are also in accordance with a combined analysis of previ-
ous G2019S studies which estimated a mean prevalence of
0.9%, although this was across different populations
(Williams-Gray et al., 2006).
R1441C mutations were present in 0.4% of young-onset
and familial patients. This is in keeping with other studies
showing the rarity of LRRK2 R1441C mutations in
Caucasian populations, with previous studies reporting fre-
quencies between 0% and 0.3% (Zabetian et al., 2005;
Pankratz et al., 2006; Mo¨ller et al., 2008). To our know-
ledge, this study is the ﬁrst to systematically screen and
report on the prevalence of R1441C mutations in young-
onset and/or familial Parkinson’s disease in the UK.
Almost half of our LRRK2 carriers did not report a
family history of Parkinson’s disease. Although the ﬁrst
reports of LRRK2 mutations were in families with multiple
affected members, later studies have shown that a large
proportion of LRRK2 carriers do not have other family
members affected by Parkinson’s disease (Gilks et al.,
2005; Ozelius et al., 2006). This is likely due to the reduced
penetrance of LRRK2 mutations. The penetrance of both
the G2019S and R1441C mutations is incomplete (24% to
42% up to age 80 for G2019S), strongly age-dependent
and increases in a linear fashion (Clark et al., 2006;
Ozelius et al., 2006; Healy et al., 2008; Lee et al., 2017).
As the population ages, it is likely that increasing numbers
of LRRK2 relatives will develop Parkinson’s disease as a
result of LRRK2 mutations, and the prevalence of this form
of Parkinson’s disease will increase in the UK.
As reported in some previous studies (Di Fonzo et al.,
2005; Gilks et al., 2005; Kay et al., 2006; Haugarvoll
et al., 2008), we found that LRRK2 carriers presented
with a range of age at onsets (35 to 79 years). LRRK2
mutations were also more common in young-onset patients
(2.2%) than in late-onset patients (0.5%). However, a com-
bined analysis of all studies in MDSGene showed that the
majority (94%) of LRRK2 carriers have late age at onset
(Trinh et al., 2018). Our ﬁndings do not support this pat-
tern and further work must be done to clarify this. It may
be that studies included in MDSGene were more likely to
screen late-onset patients and not young-onset patients for
LRRK2. This is difﬁcult to assess as MDSGene only com-
pares characteristics of mutation carriers and not non-
carriers. Our ﬁndings may have implications for genetic
testing where, in the UK, LRRK2 testing is recommended
for late-onset patients with a family history of Parkinson’s
disease. We suggest that LRRK2 should be tested more
frequently in young-onset patients, even those without a
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family history of Parkinson’s disease; however, additional
studies in both young-onset and late-onset patients are
needed.
We report two distinct G2019S haplotypes, in keeping
with previous studies showing the mutation has been
found in three major haplotypes. Haplotype 1 is the most
common, present in European and North American popu-
lations of European, Arab and Jewish origin (Goldwurm
et al., 2005; Kachergus et al., 2005; Ozelius et al., 2006;
Lesage et al., 2010; Zabetian et al., 2006a). Haplotype 2
has been reported in North American families of European
origin (Zabetian et al., 2006a) and French families (Lesage
et al., 2010). The third haplotype has been found in
Japanese patients (Zabetian et al., 2006b). We show the
presence of both haplotype 1 and haplotype 2 in our pa-
tients. These distinct haplotypes suggest there have been at
least two independent founding events from which the
G2019S mutation arose, one likely from an ancient
Middle Eastern founder (Ozelius et al., 2006; Zabetian
et al., 2006a; Lesage et al., 2010).
The R1441C mutation in LRRK2 has also been found on
at least two distinct haplotypes. The ﬁrst haplotype is re-
ported in a North American family originating from
England (Wszolek et al., 1995; Zimprich et al., 2004)
and in Flemish-Belgian families (Haugarvoll et al., 2008;
Nuytemans et al., 2008), suggesting a common founder.
The second haplotype is present in Italian, German,
Spanish, North American and Iranian patients (Zimprich
et al., 2004; Haugarvoll et al., 2008; Shojaee et al.,
2009). These haplotypes suggest that the R1441C mutation
also arose in two independent events/founders, rather than
a single ancient founder. Our constructed R1441C haplo-
types were consistent with previous reports but we were
unable to distinguish between the two different haplotypes.
We did not ﬁnd any differences in motor or non-motor
features between LRRK2 carriers and non-carriers. Several
studies and reviews suggest that LRRK2 mutations are
associated with a more benign disease course, less severe
clinical symptoms (Nichols et al., 2005), lower risk of cog-
nitive impairment and better cognitive performance (Healy
et al., 2008; Srivatsal et al., 2015; Kasten et al., 2017). The
MDSGene systematic review also suggested that LRRK2
carriers have a good response to L-DOPA, late age at
onset and absence of atypical signs (Trinh et al., 2018).
However, other studies have not conﬁrmed these ﬁndings
(Lesage et al., 2005; Haugarvoll et al., 2008; Healy et al.,
2008; Alcalay et al., 2010b; Belarbi et al., 2010; Ben Sassi
et al., 2012; Puschmann, 2013; De Rosa et al., 2014;
Estanga et al., 2014).
SNCA mutations were ﬁrst identiﬁed in large Parkinson’s
disease families with an autosomal dominant pattern of
inheritance (Polymeropoulos et al., 1997; Muenter et al.,
1998; Singleton et al., 2003). SNCA mutations are rare in
studies of Caucasian patients (Scott et al., 1999; Berg et al.,
2005; Nuytemans et al., 2009). We found one patient car-
rying a heterozygous duplication, comprising 1.5% of pa-
tients reporting two or more additional family members
affected by Parkinson’s disease. This is in line with previous
studies reporting a mutation prevalence of 1.7% to 5.8%
in familial Parkinson’s disease patients (Farrer et al., 2004;
Iba´n˜ez et al., 2004; Nishioka et al., 2009; Bozi et al.,
2014).
It has been reported previously that SNCA mutation car-
riers have more frequent and more severe dementia, rapid
progression, hallucinations and autonomic dysfunction
(Muenter et al., 1998; Farrer et al., 2004; Fuchs et al.,
2007; Ahn et al., 2008; Nishioka et al., 2009;
Puschmann, 2013; Bonifati, 2014; Kasten et al., 2017;
Schneider and Alcalay, 2017). SNCA triplications cause a
more severe phenotype while duplications tend to cause
more ‘typical’ Parkinson’s disease (Chartier-Harlin et al.,
2004; Iba´n˜ez et al., 2004; Hernandez et al., 2016).
We were not able to compare clinical features in our
cohort because of the rarity of SNCA mutations.
Our cohort represents the largest UK-based series of
LRRK2 and SNCA carriers and non-carriers identiﬁed
from the same unselected population, including both early
and late-onset patients. In line with many previous studies,
our ﬁndings suggest that Parkinson’s disease caused by
LRRK2 mutations duplications is clinically indistinguish-
able from sporadic disease.
Young-onset Parkinson’s disease
We found pathogenic mutations in 6.3% (19/302) of
young-onset patients, including mutations in both domin-
ant and recessive genes. These are comparable to the fre-
quencies previously reported in other young-onset cohorts
(Alcalay et al., 2010a; Kilarski et al., 2012; Kim and
Alcalay, 2017). In accordance with previous studies
(Alcalay et al., 2010a; Marder et al., 2010), we show
that mutations were more common in patients with earlier
onset.
We identiﬁed compound heterozygous PRKN mutations
in 2.6% of young-onset patients. While this is lower than
other prevalence estimates in Caucasian populations
(Abbas et al., 1999; Lu¨cking et al., 2000; Lohmann
et al., 2003; Periquet et al., 2003), our ﬁndings are in ac-
cordance with a previous UK community-based study that
found that PRKN mutations accounted for 3.7% of pa-
tients with onset under 45 years (Kilarski et al., 2012).
We also identiﬁed that 3% of patients carried single het-
erozygous pathogenic mutations in PRKN and PINK1. Our
frequency of single heterozygous carriers is similar to what
has been reported in other studies, although these include
varying methods for identifying copy number variants
(Klein et al., 2007; Marder et al., 2010).
Previous studies suggest that PRKN mutations are more
common in familial patients (Alcalay et al., 2010a). We
found a trend for PRKN mutations to be more common
in familial (4.2%) than in sporadic patients (1.9%), al-
though this was not signiﬁcantly different. However, 20%
of patients with two additional family members affected
carried PRKN mutations.
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We found evidence for a shared haplotype for the
P113Xfs mutation in ﬁve carriers across three markers
spanning 242 kb. Our analysis does not include genotyping
of microsatellite markers, which are needed for more de-
tailed haplotype analysis. However, our ﬁndings are con-
sistent with previous evidence showing that point mutations
have shared haplotypes and may originate from a common
founder (Farrer et al., 2001; Periquet et al., 2001).
PINK1 mutation carriers were present in 0.7% of young-
onset patients. This is comparable to the rate reported in a
previous community-based study (Kilarski et al., 2012).
Mutations are more common in Asian and Italian patients
(Hatano et al., 2004; Valente et al., 2004; Bonifati et al.,
2005; Li et al., 2005; Tan et al., 2006), reﬂecting popula-
tion-speciﬁc allele frequencies. Our ﬁndings are consistent
with the low prevalence estimates in Northern Europe and
North American patients (Healy et al., 2004; Rogaeva
et al., 2004). However, contrary to previous reports
(Kilarski et al., 2012), we did not ﬁnd that mutations
were more frequent in patients with a family history of
Parkinson’s disease (1.1%) compared to sporadic patients
(0.5%). This may be due to the small number of PINK1
carriers in our cohort.
After controlling for age and disease duration, we found
that PRKN and PINK1 carriers had earlier age at onset,
reported more postural symptoms at diagnosis and had
better cognition compared to other young-onset patients.
This is consistent with previous studies showing that
PRKN and PINK1 mutations are generally associated
with slower disease progression and less cognitive impair-
ment (Valente et al., 2001, 2004; Lohmann et al., 2003,
2012; Bonifati et al., 2005; Tan et al., 2006; Alcalay et al.,
2014; Bonifati, 2014; Kasten et al., 2017; Kim and Alcalay,
2017). Some studies have suggested that atypical features,
such as dystonia, and psychiatric symptoms may be more
common in PINK1 and PRKN carriers (Bonifati et al.,
2005; Kasten et al., 2017; Koros et al., 2017); however,
we did not ﬁnd evidence to support this. There is also
substantial variability of the frequency of these symptoms
in previous reports (Kasten et al., 2017). Our ﬁndings are
in line with a recent MDSGene systematic review, which
suggested that recessive gene mutation carriers have less
common cognitive decline, good treatment response and
otherwise clinically typical disease (Kasten et al., 2018).
While a few conﬂicting reports suggest there are no clinical
differences between PRKN carriers and non-carriers
(Lohmann et al., 2009), our ﬁndings in a large popula-
tion-based study deﬁnitively show that there are clinical
differences between mutation carriers and non-carriers.
This may be associated with the lack of Lewy body path-
ology in the brain at post-mortem (Takahashi et al., 1994;
Mori et al., 1998), although there are small numbers of
PRKN cases with pathological data, and there is variability
in ﬁndings (Farrer et al., 2001; Schneider and Alcalay,
2017).
Limitations
Our cohort was predominantly Caucasian and no patho-
genic mutations were identiﬁed in non-Caucasian groups.
Therefore, the estimated rate of mutations has limited ap-
plication in other populations. Further large-scale studies
are needed to establish mutation prevalence in other
ethnic groups. Our results are also limited by the lack of
complete screening; exome sequencing, MLPA and PRKN
and PINK1 sequencing of all patients was not feasible due
to cost limitations and the size of the cohort. Recessive gene
mutations are rare in patients with older onset (Alcalay
et al., 2010a; Kilarski et al., 2012); however, PRKN mu-
tations have been identiﬁed in late-onset patients with onset
up to 78 years (Foroud et al., 2003; Klein et al., 2003).
Therefore, there may have been a small number of muta-
tion carriers that were not detected with our screening
methods. Our data therefore represents a minimal estimate
of the frequency of genetic mutations and true numbers
may be slightly higher. Our genetic prevalence rates are
based on both incident and prevalent cases. We have
assumed that survival and hence prevalence is not inﬂu-
enced by these genes, but if some genes e.g. PRKN and
PINK1 are associated with better survival, then we may
have under-estimated the number of cases in the general
population.
A further limitation is that, while this is a large cohort
study, the rarity of pathogenic mutations means that our
group difference comparisons may be under-powered to
detect modest phenotypic differences. Finally, our cohort
is likely to still have some biases in it, given we did not
undertake a rigorous community based study collecting all
cases of the condition.
Conclusions
We show that Mendelian gene mutations are a rare but
signiﬁcant cause of Parkinson’s disease. Patients with
PRKN and PINK1 mutations differ from other young-
onset patients in cognition and postural symptoms. In com-
bination with estimates of GBA mutation prevalence, this
large-scale, relatively unbiased study suggests that up to
10% of Parkinson’s disease patients carry known genetic
variants that could be targeted by new drug therapies in
clinical trials and future treatment.
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